Current Topic

HUMAN PAPILLOMAVIRUS VACCINE: A NEW OPPORTUNITY FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS INFECTIONS

Sneha Ambwani¹, Prabhu Prakash², Seema Surana³, Suman Bhansali⁴

Author’s Affiliation: ¹Associate Professor, Dept. of Pharmacology; ²Associate Professor, Dept. of Microbiology; ³Ass. Prof., Dept. of Microbiology; ⁴Associate professor, Dept. of PSM, Dr. S. N. Medical College, Jodhpur

Correspondence: Dr. Sneha Ambwani

INTRODUCTION

Genital human papillomavirus (HPV) is associated with number of vulvar epithelial disorders including genital warts, vulvar intraepithelial neoplasia (VIN) and some vulvar carcinomas. However, the majority of individuals infected with HPV have a subclinical transient infection that is limited by viral type, local environment factors, and the host immune response. More than 120 HPV subtype have been identified out of which more than 30 are specific for anogenital tract, 15% of which are high risk or oncogenic. HPV infects the basal and parabasal cell epithelium; transmission is enhanced by irritation, abrasion and micro trauma. It also capable of inducing a local immune deficiency thus allowing prolonged viral manifestation. Clinically two distinct types of vulvar carcinoma begin to emerge. One type is having typical keratinizing vulvar squamous carcinoma, in older women with HPV infection ranges from 2% -23% while another arise in young women, HPV-related basaloid and warty carcinoma, harbor 75%-100% HPV.

HPV related VIN tends to be asymptomatic and diagnosed on evaluation of Pap smear having, lesion which may involve vulva, periurethral and perianal areas. Vulvoscopy or biopsy can be helpful in the diagnosis. The signs and symptoms of early invasive vulvar carcinoma are same as of symptomatic VIN. Most of the females complain of persistent itching and presence of a growth, pain, burning, bleeding and dysuria. Thus VIN types 2/3 must be treated due to an increased risk of malignant transformation. A large majority of genital warts are caused by HPV 6 or 11, while HPV 16 and HPV 18 are responsible for 70% of high grade cervical dysplasia and invasive cervical cancers.

HPV VACCINE

Most HPV infections do not cause disease and genital tract infections are transient. Only few HPV (HPV-16) infected women develop an abnormal pap, indicating of high risk of developing premalignant cervical disease. Other recognized cofactors which increase the risk of invasive cervical cancer include cigarette smoking, younger age at first intercourse, high parity, long term use of oral contraceptive pills, and other sexually transmitted infections. Low risk HPV (type 6 and 11) causes benign hyper proliferative lesions.

At present, two prophylactic HPV vaccines have been licensed, which utilize recombinant DNA technology, where HPV late protein gene (encoded for outer viral capsid) is expressed in a vector. These capsid self-assembled and form viral-like particles (VLP), which mimic a natural HPV viral infection but not infectious. In terms of antigen, bivalent HPV vaccines (VLPs of 16 and 18 HPV) and quadrivalent (contain HPV 16 and 18 and VLP of 6 and 11 in addition) are available which are given by intramuscular injection in three individual doses over 6 months duration. Phase I and phase II studies show high vaccine safety, tolerability and immunogenicity. Large phase III clinical trial show efficacy for HPV-16 and 18 related high grade dysplasia for both vaccines (approaching 100% protection). Effectiveness is less among women with current prevalent infection or disease.

The immunogenicity studies of quadrivalent vaccine in girls and women after three intramuscular injections at months 0, 2 and 6 is suggest, that it is safe, tolerable and effective with specific anti HPV antibodies response. At the month 7, one month after the third dose of vaccine, seroconversion rates were 99-100% in girls and women aged 15-26 years and then declined and reaching a plateau by month 24 and remain stable at this level through to at least month 60.

Seroconversion rates of quadrivalent HPV vaccines are almost 99.6% in girls aged 9-15 years and 97-99% in older females suggestive of high efficacy in younger group. Co-administration of other vaccines e.g. hepatitis B, diphtheria/tetanus pertussis/polio virus (DPT/P) vaccine and meningococcal polysaccharide conjugate vaccine did not significantly interfere with the immune response of the either vaccine.

Immunogenicity studies of quadrivalent vaccine in girls and women after three intramuscular infections at months 0, 2 and 6 is suggest, that it is safe, tolerable and effective with specific anti HPV antibodies response. At the month 7, one month after the third dose of vaccine, seroconversion rates were 99-100% in girls and women aged 15-26 years and then declined and reaching a plateau by month 24 and remain stable at this level through to at least month 60.

Seroconversion rates of quadrivalent HPV vaccines are almost 99.6% in girls aged 9-15 years and 97-99% in older females suggestive of high efficacy in younger group. Co-administration of other vaccines e.g. hepatitis B, diphtheria/tetanus pertussis/polio virus (DPT/P) vaccine and meningococcal polysaccharide conjugate vaccine did not significantly interfere with the immune response of the either vaccine.

Immunogenicity of bivalent HPV vaccine (16, 18 types) were found higher than quadrivalent vaccine at the month 7. In addition to protecting against the four vaccine HPV types, quadrivalent HPV vaccine also provide cross protection against persistent infection and lesions caused by non-vaccine high risk HPV types (31, 33, 45, 52 and 58).
The monovalent HPV 16 vaccine (which is the same as the HPV16VLP) show efficacy for up to 9.5 years without any break through disease.

SAFETY TOLERABILITY AND DOSE
Quadrivalent HPV vaccines are generally well tolerated with few adverse effects e.g. erythema at injection site, fever, pain. Hypersensitivity (arthritis, urticaria, bronchospasm), reaction was observed in <1% of recipients. The recommended dosage regimen is 0.5 ml intramuscular injection given at 0, 2, 6 months (three doses). Quadrivalent HPV vaccine should be avoided during pregnancy, but may be given to breast feeding women.

To conclude, persistent infection of the cervix with high risk HPV types can result in the development of low grade (cervical intraepithelial neoplasia CIN or VIN) or high grade pre cancerous lesion, which can progress to invasive cervical cancer. HPV types 16 and 18 are responsible for causing a high proportion of cancer e.g. cervical, vulvar, vaginal, anal mouth or oropharyngeal cancer. Monovalent (16 type), bivalent (16 and 18) and quadrivalent (6, 11, 16, 18 types) vaccine can be used prophylactically. Quadrivalent HPV vaccine was found safe, well tolerated, both during clinical trial and during post marketing surveillance as three doses and offers high level protection against HPV.

REFERENCE